PIQ Shares Proteomics International Laboratories Ltd

ASX · ASX

$0.12 +0.00% Prices as of close 2026-10-27

Last in our picks 2026-10-15 — not in the current list; analysis below is from that screen

Diagnostic technology platform offers strategic value and recovery potential after prolonged weakness.

Future value: $0.22 (+91.30%) · 6-12 months

Signal breakdown

▸Technology adoption catalyst offset by weak recent momentum.
▾Below 50-day MA (-19.33%)
▸Volume 1.95× average — accumulation
▾Near 52-week low (2.2% of range)
▸~91% upside to price target

Is PIQ a buy right now?

Trend: PIQ is trading below the 50-day average (-14.29%), RSI 18 — oversold territory, with a 3-month return of -17.24%.

Valuation & quality: Proteomics International Laboratories Ltd trades on forward P/E -4.0, price-to-book 3.43; fundamentals show net margin -254.0%, return on equity -93.0%, revenue growth 6.7% year on year.

Analyst consensus: 1 analysts have a mean 12-month price target of A$0.43 (+258.3% vs the last close; range A$0.43 – A$0.43), consensus rating “none”.

Our screen: BUY (score 2) — Diagnostic technology platform offers strategic value and recovery potential after prolonged weakness.

Computed from end-of-day data; not personal advice.

12-month price chart

Daily close, 2026-02-08 → 2026-10-27 (AUD). Range 0.10 – 0.47.

Monthly returns

Mar 26	Apr 26	May 26	Jun 26	Jul 26	Aug 26	Sep 26	Oct 26
-14.70%	-20.70%	-39.10%	-14.30%	+16.70%	+7.10%	-6.70%	-14.30%

Fundamentals

Market cap

$19.8M

P/E (ttm)

-3.8

Forward P/E

-4.0

EPS (ttm)

$-0.05

Price / book

3.43

Beta

-0.36

Net margin

-254.0%

ROE

-93.0%

Revenue growth

6.7%

Revenue (ttm)

$3.4M

Free cash flow

$-5,884,791

Debt / equity

52-wk range

$0.10 – $0.86

Volume

96,613

Avg volume (3m)

105,093

Analyst price target

Mean target

$0.43

Low

$0.43

High

$0.43

Analysts

Consensus

NONE

Technical signals

RSI (14)

18.1

vs 50-day MA

-14.29%

1-mo return

-4.00%

3-mo return

-17.24%

Volume z-score

-0.45

About Proteomics International Laboratories Ltd

Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, and India. It provides PromarkerD, a blood test to predict chronic kidney disease in people with type 2 diabetes.

Sector: Healthcare · Industry: Biotechnology · Australia · Website

Related Biotech picks

CSL.AXCSL Limited MSB.AXMesoblast Limited IMR.AXImricor Medical System SLD.AXSaluda Medical, Inc.NUZ.AXNeurizon Therapeutics NEU.AXNeuren Pharmaceuticals DXB.AXDimerix Limited NYR.AXNyrada Inc.

Browse: all ASX stocks · Biotech picks · today's movers

General information only (Australia). This is general information, not financial product advice. It doesn't consider your objectives, financial situation or needs — consider its appropriateness and seek licensed advice before acting. Not a recommendation to buy or sell any financial product.

Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.